CCNU in the treatment of canine epitheliotropic lymphoma

Journal of Veterinary Internal Medicine

Volumn 20, Issue 1, 2006, Pages 136-143

  Williams, Laurel E ^a   Rassnick, Kenneth M ^b   Power, Helen T ^c   Lana, Susan E ^d   Morrison Collister, Kirsten E ^e   Hansen, K ^f   Johnson, Jeffrey L ^g  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c Dermatology for Animals   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e Franklin Park Animal Hospital   (United States)

^f Friendship Hospital for Animals   (United States)

^g DUKE CANCER INSTITUTE   (United States)

Author keywords

Dog; Medicine chemotherapy; Mycosis fungoides

Indexed keywords

ALKYLATING AGENT; LOMUSTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; FEMALE; MALE; MULTICENTER STUDY; MYCOSIS FUNGOIDES; RETROSPECTIVE STUDY; SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; DOG DISEASES; DOGS; FEMALE; LOMUSTINE; MALE; MYCOSIS FUNGOIDES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

CANIS FAMILIARIS;

EID: 30944470331     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[136:CITTOC]2.0.CO;2     Document Type: Article

References (44)

1. Scott DW, Miller WH, Griffen CE. Neoplastic and non-neoplastic tumors. In: Scott DW, Miller WH, Griffin CE, eds. Small Animal Dermatology. Philadelphia, PA: WB Saunders; 2001:1330-1340.
2. DeBoer DJ, Turrel JM, Moore PF. Mycosis fungoides in a dog: Demonstration of T-cell specificity and response to radiotherapy. J Am Anim Hosp Assoc 1990;26:566-572.
3. Thrall MA, Macy DW, Snyder SP, Hall RL. Cutaneous lymphosarcoma and leukemia in a dog resembling Sezary syndrome in man. Vet Pathol 1984;21:182-186.
4. Foster AP, Evans E, Kerlin RL, DM Vail. Cutaneous T-cell lymphoma with Sezary syndrome in a dog. Vet Clin Pathol 1997;26:188-192.
5. Burg G, Dummer R. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). Hist Clin Lymphoma 2000;1(Suppl 1):S41-44.
6. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: Current status and future directions. Am J Clin Dermatol 2002;3:193-215.
7. Martin AG. Bexarotene gel: A new skin-directed treatment option for cutaneous T-cell lymphomas. J Drugs Dermatol 2003;2:155-167.
8. White SD, Rosychuk RAW, Scott KV, et al. Use of isotretinoin an etretinate for the treatment of benign cutaneous neoplasia and cutaneous lymphoma in dogs. J Am Vet Med Assoc 1993;202:387-391.
9. Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoides: Management with topical nitrogen mustard. J Clin Oncol 1987;5:1796-1803.
10. Vonderheid EC, Tan ET, Kantor AF, et al. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989;20:416-428.
11. Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther 2003;16:288-298.
12. Jones G, Wilson LD, Fox-Goguen L. Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am 2003;17:1421-1434.
13. Hoppe RT. Mycosis fungoides: Radiation therapy. Dermatol Ther 2003;16:347-354.
14. Meleo KA. The role of radiotherapy in the treatment of lymphoma and thymoma. Vet Clin North Am Small Anim Pract 1997;27:115-129.
15. Zenoble RD, George JW. Mycosis fungoides-like disease in a dog. J Am Anim Hosp Assoc 1980;16:203-208.
16. McKeever PJ, Grindem CK, Stevens JB, Osborne CA. Canine cutaneous lymphoma. J Am Vet Med Assoc 1982;180:531-536.
17. Hamilton TA, Cook JR, Braund KG, et al. Vincristine-induced peripheral neuropathy in a dog. J Am Vet Med Assoc 1991;198:635-638.
18. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395-398.
19. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (Lomustine). J Vet Intern Med 1999;13:601-605.
20. Veterinary Cooperative Oncology Group. Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
21. Simon R, Lee YJ. Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep 1982;66:37-42.
22. Stone MS, Goldstein MA, Cotter SM. Comparison of two protocols for induction of remission in dogs with lymphoma. J Am Anim Hosp Assoc 1991;27:315-321.
23. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-295.
24. Myers NC, Moore AS, Rand WM, et al. Evaluation of a multidrug combination chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 1997;11:333-339.
25. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998;12:465-470.
26. Lemarie SL, Eddlestone SM. Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog (case report). Vet Dermatol 1997;8:41-46.
27. Ridyard AE, Rhind SM, French AT, et al. Myasthenia gravis associated with cutaneous lymphoma in a dog. J Small Anim Pract 2000;41:348-351.
28. Cowall DE, MacVittie TJ, Parker GA, Weinberg SR. Effects of low-dose total-body irradiation on canine bone marrow function and canine lymphoma. Exp Hematol 1981;9:581-587.
29. Laing EJ, Fitzpatrick PJ, Binnington AG, et al. Half-body radiotherapy in the treatment of canine lymphoma. J Vet Intern Med 1989;3:102-108.
30. Gustafson NR, Lana SE, Mayer MN, LaRue SM. A preliminary assessment of whole-body radiotherapy interposed within a chemotherapy protocol for canine lymphoma. Vet Comp Oncol 2004;2:125-131.
31. Williams LE, Johnson JL, Hauck ML, et al. Chemotherapy followed by half-body radiation therapy for canine lymphoma. J Vet Intern Med 2004;18:703-709.
32. Wilson LD, Jones GW, Kacinski BM, et al. Cutaneous T-cell lymphomas. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2316-2330.
33. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
34. Bergman PJ, Ogilvie GK, Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 1996;10:354-359.
35. van Haselen CW, Flens MJ, Scheper RJ, et al. Multidrug resistance related proteins in primary cutaneous lymphomas. Adv Exp Med Biol 1999;457:119-131.
36. Tannok IF. Experimental chemotherapy. In: Tannok IF, Hill RP, eds. The Basic Science of Oncology. New York, NY: McGraw-Hill; 1992:338-359.
37. Muche JM, Gellrich S, Sterry W. Treatment of cutaneous T-cell lymphomas. Semin Cutan Med Surg 2000;19:142-148.
38. Smith BD, Wilson LD. Management of mycosis fungoides. Part 2. Treatment. Oncology (Huntingt) 2003;17:1419-1428.
39. Bouchard H. Epitheliotropic lymphoma in a dog. Can Vet J 2000;41:628-630.
40. Czasch S, Risse K, Baumgartner W. Central nervous system metastasis of a cutaneous epitheliotropic lymphosarcoma in a dog. J Comp Pathol 2000;123:59-63.
41. Donaldson D, Day MJ. Epitheliotropic lymphoma (mycosis fungoides) presenting as blepharoconjunctivitis in an Irish setter. J Small Anim Pract 2000;41:317-320.
42. Langenbach A, McManus PM, Hendrick MJ, et al. Sensitivity and specificity of methods of assessing the regional lymph nodes for evidence of metastasis in dogs and cats with solid tumors. J Am Vet Med Assoc 2001;218:1424-1428.
43. Williams LE, Packer RA. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987-2001). J Am Vet Med Assoc 2003;222:1234-1236.
44. Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (Lomustine) chemotherapy in dogs. J Vet Intern Med 2004;18:75-80.